Pipeline

We are developing two primary compounds, NVC-101 (also referred to as NeutroPhase™) and auriclosene (NVC-422), which we intend to use in the development of products to treat various bacterial infections. Auriclosene is our lead compound in a new class of antimicrobial compounds that we call the Aganocide® compounds.